Compare AMKR & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | DVA |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Misc Health and Biotechnology Services |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 10.1B |
| IPO Year | 1997 | 2002 |
| Metric | AMKR | DVA |
|---|---|---|
| Price | $46.79 | $149.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | $52.88 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 3.5M | 749.5K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | ★ 4.90 | N/A |
| EPS | 1.50 | ★ 9.84 |
| Revenue | $4,052,650,000.00 | ★ $13,643,069,000.00 |
| Revenue This Year | $13.21 | $3.80 |
| Revenue Next Year | $9.80 | $3.04 |
| P/E Ratio | $30.95 | ★ $15.25 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $14.03 | $101.00 |
| 52 Week High | $57.09 | $159.42 |
| Indicator | AMKR | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 54.44 |
| Support Level | $46.48 | $146.00 |
| Resistance Level | $47.28 | $150.69 |
| Average True Range (ATR) | 1.99 | 4.67 |
| MACD | 0.17 | -1.70 |
| Stochastic Oscillator | 80.37 | 23.29 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.